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Conclusions: The implementation of TID permits to take decisions 
about the system weakness. In the PC the adopted measures, after 
the analysis of TID,decrease the APD, and thus improve the outcome 
with similar acute effects.  
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Purpose/Objective: Incident management is an important aspect of 
risk management and quality assurance in the field of radiation 
therapy. Traditionally, actual incidents (AIs) that impact the patient 
and near misses (NMs) that are detected prior to reaching the patient 
have been analyzed and managed in a similar manner. This study aims 
to determine if AIs and NMs share similar characteristics and can be 
used interchangeably for risk assessment and continuous quality 
improvement. 
Materials and Methods: Safety reports submitted between January 
2010 and June 2012 at a Canadian radiotherapy centre were classified 
based on guidelines from the World Health Organization as follows: 
Incident nature (AI, NM), incident type (equipment, documentation, 
process) and stage of origin (booking/simulation, planning, treatment 
delivery). Incident type and stage of origin were compared between 
AIs and NMs. 
Results: Among the 552 cases retrieved, 25% were classified as AIs and 
75% as NMs. There were significant differences in the distribution of 
incident type (p<0.001) and stage of origin (p<0.001) between AIs and 
NMs. AIs were more likely to involve equipment errors (34% vs 8%), 
whereas NMs were more likely to involve documentation errors (42% 
vs. 9%). The majority of AIs originated at the treatment delivery stage 
(51%), while the majority of NMs originated at the booking/simulation 
stage (52%). Cross tabulation of the data revealed other interesting 
patterns. Process errors were the most common type of incident in 
both groups (AI 56%, NM 51%) but the stage of origin differed. For AIs, 
the majority of process errors occurred at the treatment delivery 
stage (48%) compared to the booking/simulation stage for NMs (56%). 
Similarly, while a comparable proportion of AIs and NMs originated at 
the planning stage, the majority of AIs were process errors (74%) while 
most of the NMs were documentation errors (54%). 
 
 
Conclusions: In this study, NMs were found to have different 
characteristics than AIs. The traditional practice of analyzing and 
managing NMs and AIs in a similar manner is not the optimal approach 
to managing risk in radiotherapy, as NMs may reflect different failure 
modes than AIs. NMs and AIs should be analyzed separately to identify 
important opportunities for quality improvement. 
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Purpose/Objective: ARISTOTLE is a UK NCRI phase III trial comparing 
standard versus novel chemo-radiotherapy as pre-operative treatment 
for MRI defined locally advanced rectal cancer. The pre-trial 
radiotherapy quality assurance (RTQA) process for ARISTOTLE is aimed 
at ensuring that participating centres comply with the outlining, 
planning and reporting standards required by the trial protocol. This 
paper summarises the initial results from the pre-trial RTQA 
assessments for participating centres. 
Materials and Methods: The main requirements of the pre-trial QA 
process are trial questionnaires, outlining and planning benchmark 
cases, process document and case submission. Specific aspects include 
the following.  Outlining Exercise. A reference CT dataset is provided 
for outlining. Participants are required to outline adhering to protocol 
and utilising naming conventions. It is a requirement that each RT 
centre returns at least one outlining benchmark case, reviewed and 
approved by the local Principal Investigator.  Planning Cases. Two 
planning benchmark cases are supplied, with volumes pre-delineated – 
one prone and one supine. Centres are requested to plan the example 
relating to the position they intend to use for trial patients. Planning 
is required to be performed as per protocol, with attention paid to 
the dose volume objectives for both target coverage and maximum 
patient doses. Planning QA includes submission and evaluation of a 
Plan Assessment Form using standardised metrics for reporting, which 
is completed and returned for the planning case. 
Results: Forty UK radiotherapy centres have participated in the QA 
process so far, with full QA completed for 32. Some centres returned 
planning cases from more than one clinician. The total number of 
cases returned to date is 40. Reports were submitted to participating 
centres when QA was completed, with specific dialogue to clarify and 
address points of uncertainty. Initial review of QA reports received to 
date suggests some evidence of protocol mis-interpretation with 
respect to the following. 
Outlining. Ipsilateral obturator internus (required to be outlined 
within CTV by protocol) not included by 11 clinicians of the 40 who 
have submitted to date. The contralateral obturator internus (not 
required to be outlined within CTV by protocol) was included by 5 
clinicians.  
  Group A Group B 
Age (years)  68.1 67.2 
Low risk PC (%)  10.3 25.0 
Medium risk PC (%) 44.8 27.8 
High Risk PC (%)  44.9 47.2 
APD (days)  6.4 (5.2, 7.5) 4.7 (3.4, 5.9) 
PAE (%) Grade 0  50.0 27.0 
PAE (%) Grade 1  34.5 54.1 
PAE (%) Grade 2  12.1 16.2 
PAE (%) Grade 3  3.4 2.7 
Estimated BF (%)   5.5 4.0  
